InvestSMART

Pilbara Gold Limited (ASX: PGL) - Announcements

Current share price for PGL : $0.540 0.01 (1.89%)+

ASX company news and announcements for Pilbara Gold Limited (PGL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pilbara Gold Limited (PGL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pilbara Gold Limited (PGL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pilbara Gold Limited (PGL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$126 Progen Pharmaceuticals Ltd signs Binding License Term Sheet 28 Dec 2012 8:29AM $0.300 $0.540 risen by 80%
$126 AGM Capital Raising Presentation 29 Nov 2012 12:05PM $0.240 $0.540 risen by 125%
$126 PI-88 Phase II Melanoma Clinical Study Results 17 Oct 2012 2:00PM $0.260 $0.540 risen by 107.69%
$126 PI-88 Phase III Update 27 Sep 2012 10:09AM $0.255 $0.540 risen by 111.76%
$126 PG545 Update 21 Sep 2012 9:44AM $0.270 $0.540 risen by 100%
$126 Preliminary Final Report 31 Aug 2012 3:49PM $0.200 $0.540 risen by 170%
$126 Progen Pharmaceuticals Granted Additional US Patent 17 Jul 2012 8:30AM $0.220 $0.540 risen by 145.45%
$126 Progen Pharmaceuticals Granted Australian Patent 30 May 2012 12:04PM $0.120 $0.540 risen by 350%
$126 Progen Presents PG545 at AACR Meeting in Chicago 4 Apr 2012 9:52AM $0.190 $0.540 risen by 184.21%
$126 Half Yearly Report and Accounts 28 Feb 2012 5:23PM $0.200 $0.540 risen by 170%
$126 Progen Licensee Receives IND Approval in China for PI-88 31 Jan 2012 10:26AM $0.170 $0.540 risen by 217.65%
$126 PG545 Update 21 Dec 2011 9:29AM $0.150 $0.540 risen by 260%
$126 Progen Licensee Receives IND Approval in Korea for PI-88 17 Oct 2011 2:12PM $0.150 $0.540 risen by 260%
$126 Licensee Commences Recruitment, End of Settlement Agreement 26 Sep 2011 12:13PM $0.200 $0.540 risen by 170%
$126 Closure of PG545 Phase 1a Clinical Trial 20 Sep 2011 4:33PM $0.210 $0.540 risen by 157.14%
$126 Preliminary Final Report 23 Aug 2011 12:32PM $0.210 $0.540 risen by 157.14%
$126 Progen Subsidiary Secures New Manufacturing Contracts 20 Jul 2011 12:13PM $0.250 $0.540 risen by 116%
$126 PI-88 Receives Orphan Medicinal Product Designation 29 Jun 2011 1:03PM $0.270 $0.540 risen by 100%
$126 PI-88 Phase III Update 23 Jun 2011 10:27AM $0.300 $0.540 risen by 80%
$126 Progen Board and Senior Management Changes 16 Jun 2011 10:09AM $0.240 $0.540 risen by 125%
$126 Completes Epi Pharmaceuticals Inc Formation and Reduces Risk 19 May 2011 9:17AM $0.305 $0.540 risen by 77.05%
$126 Progen Licensee Gains Approval for Phase III Clinical Trial 19 Apr 2011 1:24PM $0.335 $0.540 risen by 61.19%
$126 Progen`s PG11047 Clinical Study Completes Enrolment 6 Apr 2011 10:27AM $0.330 $0.540 risen by 63.64%
$126 PG545 Presented at the AACR Annual Meeting 5 Apr 2011 10:26AM $0.335 $0.540 risen by 61.19%
$126 Progen Enters Diabetes Collaboration with ANU 30 Mar 2011 10:14AM $0.340 $0.540 risen by 58.82%

451 - 475 of 577 results

Page 19 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.